SURVYR

MXCT

MaxCyte, Inc.
$1.54
+$0.03 (1.99%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-58%-39%-21%-2%+17%Oct 2025Oct 2026Apr 202652w high $1.8052w low $0.64
MXCTSPY
Wall St. Highest PT $5.00 (+224.7%) Wall St. Avg PT $4.11 (+166.7%)
$1$2$3$4$5POC $1Hi $5Avg $4
Underwater Drawdown %Max DD -61.6%Current -12.5%
0.0%-61.6%
Relative Strength vs SPY-13.5% vs SPYUnderperforming
+65%0%-65%
1W
+$0.11 (7.69%)
1M
+$0.37 (31.62%)
3M
+$0.49 (46.67%)
6M
+$0.66 (75.60%)
YTD
−$0.01 (0.65%)
1Y
+$0.00 (0.00%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
4 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$1.54
Average target$4.11
+$2.57 (+166.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$2.43
Median$4.11
High$5.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-03-25 · Craig-Hallum reiterated Buy on MXCT
Downgrade
2025-08-11 · BTIG downgraded MXCT from Buy to Neutral
Downgrade
2025-08-07 · William Blair downgraded MXCT from Outperform to Market Perform
Reiterated
2025-03-12 · Stifel reiterated Buy on MXCT
Reiterated
2024-04-23 · Stephens & Co. reiterated Overweight on MXCT
Reiterated
2024-03-13 · Stephens & Co. reiterated Overweight on MXCT
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$147.6M
P/E (next 12 months, estimated)-5.8
52-week range$0.64 – $1.80
Revenue growth (latest quarter vs a year ago)-14.5%
Dividend yieldNo dividend
Analyst consensusStrong Buy (4)
Average analyst price target$4.11 (+167%)

What they do

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for MXCT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MXCT earningsNext report in 13 days
Next report · quarter Sep 2026
Tue Nov 10, 2026After the close
EPS consensus-$0.08 range -$0.09–-$0.08
Revenue consensus$7.5M 5 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026-$0.08est -$0.09+14.3%Above estimates
Mar 24, 2026-$0.06est -$0.08+32.1%Above estimates
Nov 12, 2025-$0.09est -$0.10+12.2%Above estimates
Aug 6, 2025-$0.12est -$0.10−17.6%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 01:31:22 ET
24-0824-1125-0325-0525-0825-1126-0326-08-0.130.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$7.3M-14.5%
2026-03-31$9.7M–
2025-12-31$7.3M–
2025-09-30$6.8M–
2025-06-30$8.5M–

News & catalysts

More news
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
GlobeNewswire · Oct 14
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Zacks · Oct 06
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
GlobeNewswire · Sep 23
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 11
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19
Rating changes
Reiterated
2026-03-25 · Craig-Hallum reiterated Buy on MXCT
Downgrade
2025-08-11 · BTIG downgraded MXCT from Buy to Neutral
Downgrade
2025-08-07 · William Blair downgraded MXCT from Outperform to Market Perform
Reiterated
2025-03-12 · Stifel reiterated Buy on MXCT
Reiterated
2024-04-23 · Stephens & Co. reiterated Overweight on MXCT
Reiterated
2024-03-13 · Stephens & Co. reiterated Overweight on MXCT

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 01:31:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026